|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-4-30
|
|
pubmed:abstractText |
Modulation of cAMP levels has been linked to insulin secretion in preclinical animal models and in humans. The high expression of PDE-10A in pancreatic islets suggested that inhibition of this enzyme may provide the necessary modulation to elicit increased insulin secretion. Using an HTS approach, we have identified quinoline-based PDE-10A inhibitors as insulin secretagogues in vitro. Optimized compounds were evaluated in vivo where improvements in glucose tolerance and increases in insulin secretion were measured.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BarucciNicoleN,
pubmed-author:BreuhausMarinaM,
pubmed-author:BullockWilliam HWH,
pubmed-author:BurkeJenniferJ,
pubmed-author:CantinLouis-DavidLD,
pubmed-author:ClausThomas HTH,
pubmed-author:DalyMichelleM,
pubmed-author:DecarrLynnL,
pubmed-author:Gore-WillseAnnA,
pubmed-author:GunnDavidD,
pubmed-author:Hoover-LittyHelanaH,
pubmed-author:KumarasingheEllalahewage SES,
pubmed-author:LiYaxinY,
pubmed-author:LiangSidney XSX,
pubmed-author:LivingstonJames NJN,
pubmed-author:LowingerTimothyT,
pubmed-author:MacdougallMargitM,
pubmed-author:MagnusonStevenS,
pubmed-author:OgutuHerbert OHO,
pubmed-author:OlagueAlanA,
pubmed-author:Ott-MorganRondaR,
pubmed-author:SchoenleberRobert WRW,
pubmed-author:SweetLaurel JLJ,
pubmed-author:TersteegenAdrianA,
pubmed-author:WickensPhilipP,
pubmed-author:ZhangZhonghuaZ,
pubmed-author:ZhuJianJ,
pubmed-author:ZhuLeiL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2869-73
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
PDE-10A inhibitors as insulin secretagogues.
|
|
pubmed:affiliation |
Department of Chemistry Research, Bayer Pharmaceuticals Corporation, West Haven, CT 06516, USA. Louis-David.Cantin.Cantin@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article
|
